Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System

Microbot Medical Inc.

World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.
First robotic Y-90 radioembolization mapping for liver cancer completed using the same system.
LIBERTY is FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Limited Market Release started November 2025; Full Market Release planned for April 2026 at SIR conference.
BPH affects approximately 40 million men in the U.S.; LIBERTY aims to become standard of care for PAE.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-012812
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2026-03-26T23:59:59+00:00
discovered_at: 2026-05-14T18:02:37.911848+00:00
generated_at: 2026-05-15T08:57:03.448465+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-012812
json_url: https://secwatch.observer/filing/0001493152-26-012812.json
markdown_url: https://secwatch.observer/filing/0001493152-26-012812.md
text_url: https://secwatch.observer/filing/0001493152-26-012812.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226012812/0001493152-26-012812-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226012812/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-012812

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.